Showing 35,164 results

Vaginal rings & topical PrEP

Promising new PrEP method undergoes first safety study for anal sex

News
24 February 2023
Mental & emotional health problems

Anxiety, Depression, and Different Types of MI in people living with HIV

Editor's pick
TheBodyPro
24 February 2023
Mental & emotional health & wellbeing

Combinations containing TAF and cobicistat linked to physical depression symptoms in women with HIV

News
23 February 2023

CROI 2023: Des injections trimestrielles de PrEP peuvent être efficaces chez les femmes, Jeudi 23 février 2023

February 2023

CROI 2023: PrEP, per le donne potrebbe essere efficace anche una sola iniezione trimestrale, giovedì 23 febbraio 2023

February 2023

КРОИ 2023: Ежеквартальное введение инъекционного ДКП-препарата может быть эффективным у женщин, Четверг, 23 февраля 2023 г.

February 2023

CROI 2023: Las inyecciones trimestrales de PrEP pueden ser eficaces para las mujeres, Jueves, 23 de febrero de 2023

February 2023

CROI 2023: Injeções trimestrais de PrEP podem ser eficazes para mulheres, Quinta-feira, 23 de fevereiro de 2023

February 2023
Combatting stigma

Silence Will Not Save You

Editor's pick
TheBody
23 February 2023
Injectable & long-acting HIV treatment

CROI 2023: Lenacapavir and two broadly neutralising antibodies for treatment Video

February 2023
Resistance

Treating HIV? Memorize These 12 HIV Resistance Mutations. Yes, Really.

Editor's pick
TheBodyPro
23 February 2023
Hepatitis B

ALLIANCE trial shows positive HIV/HBV coinfection treatment data

Editor's pick
Healio
23 February 2023
HIV in the arts & media

‘The First Fallen’ Review: A Remembrance of Those Passed

Editor's pick
The New York Times
23 February 2023
Injectable & long-acting PrEP

Modeling study shows that long-acting injectable cabotegravir has the potential to significantly reduce new HIV infections

Editor's pick
Clinton Health Access Initiative
23 February 2023
The search for an HIV prevention vaccine

A HIV Vaccine Candidate Demonstrates Its Safety and Capacity to Induce an Immune Response

Editor's pick
ANRS
23 February 2023
New & experimental HIV treatments

Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection

Editor's pick
Merck press release
23 February 2023
The search for a cure

The London Patient: ‘I feel like I won the lottery: I have been cured of two incurable diseases’

Editor's pick
El País
23 February 2023
Pharmaceutical industry

Gilead, Teva and J&J's HIV antitrust case inches closer to trial as judge keeps most claims on the table

Editor's pick
FiercePharma
23 February 2023
Health problems in children & young people

Children's HIV Deaths in Africa Largely Preventable

Editor's pick
MedPage Today
23 February 2023
Infant feeding

U.S. Guidelines Embrace Breastfeeding as Option for Parents Living With HIV

Editor's pick
TheBodyPro
23 February 2023
Sex workers

Economic Empowerment Can Reduce HIV Along African Border Routes

Editor's pick
TheBody
23 February 2023
Access to healthcare

One year on: We must sustain the HIV response in Ukraine

Editor's pick
UNAIDS
23 February 2023
Injectable & long-acting HIV treatment

San Francisco shows that long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression

News
23 February 2023
Injectable & long-acting HIV treatment

ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of HIV-1

Editor's pick
ViiV press release
23 February 2023